Alterations in circulating angiogenic and anti-angiogenic factors in type 2 diabetic patients with neuropathy

Cell Biochemistry and Function

Volumn 32, Issue 2, 2014, Pages 155-163

  Motawi, Tarek Kamal ^a   Rizk, Sherine Maher ^a   Ibrahim, Ihab Abdel Rahman ^b   El Emady, Yasmin Farid ^c  

^a CAIRO UNIVERSITY   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

^c Holding Company for Biological Products and Vaccines (VACSERA)   (Egypt)

Author keywords

Diabetic peripheral neuropathy; Endothelin 1; Endothelin 1 mRNA; Nitric oxide; Soluble endoglin; Vascular endothelial growth factor

Indexed keywords

ENDOGLIN; ENDOTHELIN 1; NITRIC OXIDE; VASCULOTROPIN; BIOLOGICAL MARKER; CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; MESSENGER RNA; VASCULOTROPIN A;

ADULT; ANGIOGENESIS; ARTICLE; CONTROLLED STUDY; DIABETIC NEUROPATHY; DIABETIC PATIENT; DIABETIC PERIPHERAL NEUROPATHY; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK FACTOR; AGED; BLOOD; CASE CONTROL STUDY; COMPLICATION; DIABETIC NEUROPATHIES;

ADULT; AGED; ANTIGENS, CD; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; ENDOTHELIN-1; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE; RECEPTORS, CELL SURFACE; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84895527026     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.2987     Document Type: Article

References (65)

1. Pop-Busui R, Lu J, Lopes N, Jones TL. BARI 2D investigators. Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort. J Peripher Nerv Syst 2009; 14: 1-13.
2. van Schie CH. Neuropathy: mobility and quality of life. Diabetes Metab Res Rev 2008; 24(Suppl 1): S45-S51.
3. Vinik AI, Park TS, Stansberry KB, Pittenger GL. Diabetic neuropathies. Diabetologia 2000; 43: 957-973.
4. Schratzberger P, Walter DH, Rittig K, et al. Reversal of experimental diabetic neuropathy by VEGF gene transfer. J Clin Invest 2001; 107: 1083-1092.
5. Low PA, Lagerlund TD, McManis PG. Nerve blood flow and oxygen delivery in normal, diabetic, and ischemic neuropathy. Int Rev Neurobiol 1989; 31: 355-438.
6. Cameron NE, Cotter MA. Neurovascular dysfunction in diabetic rats. Potential contribution of autoxidation and free radicals examined using transition metal chelating agents. J Clin Invest 1995; 96: 1159-1163.
7. Boulton AJ. Diabetic neuropathy: classification, measurement and treatment. Curr Opin Endocrinol Diabetes Obes 2007; 14: 141-145.
8. Gui C, Li SK, Nong QL, Du F, Zhu LG, Zeng ZY. Changes of serum angiogenic factors concentrations in patients with diabetes and unstable angina pectoris. Cardiovasc Diabetol 2013; 12: 1-34.
9. Hoke A, Sun HS, Gordon T, Zochodne DW. Do denervated peripheral nerve trunks become ischemic? The impact of chronic denervation on vasa nervorum. Exp Neurol 2001; 172: 398-406.
10. Ferrara N, Gerber HP, Le Couter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-676.
11. Raab S, Plate KH. Different networks, common growth factors: shared growth factors and receptors of the vascular and the nervous system. Acta Neuropathol 2007; 113: 607-626.
12. López-Novoa JM. Soluble endoglin is an accurate predictor and a pathogenic molecule in pre-eclampsia. Nephrol Dial Transplant 2007; 22: 712-714.
13. Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006; 2: 642-649.
14. Strzalka-Mrozik B, Nowak A, Gola J, Kowalczyk M, Kapral M, Mazurek U. Factors associated with changes in endothelin-1 gene expression in patients with diabetic retinopathy in type 2 diabetes mellitus. Mol Vis 2010; 16: 1272-1279.
15. Kakizawa H, Itoh M, Itoh Y, et al. The relationship between glycemic control and plasma vascular endothelial growth factor and endothelin-1 concentration in diabetic patients. Metabolism 2004; 53: 550-555.
16. Vareniuk I, Pacher P, Pavlov IA, Drel VR, Obrosova IG. Peripheral neuropathy in mice with neuronal nitric oxide synthase gene deficiency. Int J Mol Med 2009; 23: 571-580.
17. Star RA. Intrarenal localization of nitric oxide synthase isoforms and soluble guanylyl cyclase. Clin Exp Pharmacol Physiol 1997; 24: 607-610.
18. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109-142.
19. Heltianu C, Guja C. Role of nitric oxide synthase family in diabetic neuropathy. J Diabetes Metab 2011; S5: 002.
20. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care 2012; 35(Suppl 1): S11-63.
21. Berge KE, Djurovic S, Muller HJ, Alestrom P, Berg K. Studies on effects of Lp(a) lipoprotein on gene expression in endothelial cells in vitro. Clin Genet 1997; 52: 314-325.
22. Ercolani L, Florence B, Denaro M, Alexander M. Isolation and complete sequence of functional glyceraldehyde-3-phosphate dehydrogenase gene. J Biol Chem 1988; 263: 15335-15341.
23. Bustin SA. Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems. J Mol Endocrinol 2002; 29: 23-39.
24. Tomlinson DR, Gardiner NJ. Glucose neurotoxicity. Nat Rev Neurosci 2008; 9: 36-45.
25. Meleth AD, Agron E, Chan CC, et al. Serum inflammatory markers in diabetic retinopathy. Invest Ophthalmol Vis Sci 2005; 46: 4295-4301.
26. Cavusoglu AC, Bilgili S, Alaluf A, et al. Vascular endothelial growth factor level in the serum of diabetic patients with retinopathy. Ann Ophthalmol (Skokie) 2007; 39: 205-208.
27. Ozturk BT, Bozkurt B, Kerimoglu H, Okka M, Kamis U, Gunduz K. Effect of serum cytokines and VEGF levels on diabetic retinopathy and macular thickness. Mol Vis 2009; 15: 1906-1914.
28. Murata T, Nagai R, Ishibashi T, Inomuta H, Ikeda K, Horiuchi S. The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas. Diabetologia 1997; 40: 764-769.
29. Natarajan R, Bai W, Lanting L, Gonzales N, Nadler J. Effects of high glucose on vascular endothelial growth factor expression in vascular smooth muscle cells. Am J PhysioI 1997; 273: H2224-H2231.
30. Treins C, Giorgetti-Peraldi S, Murdaca J, Van Obberghen E. Regulation of vascular endothelial growth factor expression by advanced glycation end products. J Biol Chem 2001; 276: 43836-43841.
31. Blann AD, Belgore FM, McCollum CN, Silverman S, Lip PL, Lip GY. Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or Type II diabetes. Clin Sci (Lond) 2002; 102: 187-194.
32. Cameron NE, Eaton SE, Cotter MA, Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 2001; 44: 1973-1988.
33. Polydefkis M, Griffin JW, McArthur J. New insights into diabetic polyneuropathy. JAMA 2003; 290: 1371-1376.
34. Sondell M, Lundborg G, Kanje M. Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system. J Neurosci 1999; 19: 5731-5740.
35. Schratzberger P, Schratzberger G, Silver M, et al. Favorable effect of VEGF gene transfer on ischemic peripheral neuropathy. Nat Med 2000; 6: 405-413.
36. Wirostko B, Wong TY, Simó R. Vascular endothelial growth factor and diabetic complications. Prog Retin Eye Res 2008; 27: 608-621.
37. Zachary I. Neuroprotective role of vascular endothelial growth factor: signalling mechanisms, biological function, and therapeutic potential. Neurosignals 2005; 14: 207-221.
38. Sun Y, Jin K, Childs JT, Xie L, Mao XO, Greenberg DA. Increased severity of cerebral ischemic injury in vascular endothelial growth factor-B-deficient mice. J Cereb Blood Flow Metab 2004; 24: 1146-1152.
39. Valabhji O, Dhanjil S, Nicolades AN, Elkeles RS, Sharp P. Correlation between carotid artery dispensability and serum vascular endothelial growth factor concentrations in diabetic subjects and nondiabetic subjects. Metabolism 2001; 50: 825-829.
40. Chiarelli F, Santilli F, Mohn A. Role of growth factors in the development of diabetic complications. Horm Res 2000; 53: 53-67.
41. Zehetner C, Kirchmair R, Kralinger M, Kieselbach G. Correlation of vascular endothelial growth factor plasma levels and glycemic control in patients with diabetic retinopathy. Acta Ophthalmol 2013; Mar 4. DOI: 10.1111/aos.12081
42. Lee NY, Golzio C, Gatza CE, Sharma A, Katsanis N, Blobe GC. Endoglin regulates PI3-kinase/Akt trafficking and signaling to alter endothelial capillary stability during angiogenesis. Mol Biol Cell 2012; 23: 2412-2423.
43. Studyy-Valeria B, Maddalena G, Enrica V, Onofrio T, Gaetano B. Endoglin (CD105) expression in the human heart throughout gestation. Immunohistoch Reprod Sci 2008; 15: 1018-1026.
44. Taddei S, Ghiadoni L, Virdis A, Versari D, Salvetti A. Mechanisms of endothelial dysfunction: clinical significance and preventive non-pharmacological therapeutic strategies. Curr Pharm 2003; 9: 2385-2402.
45. Fernández-L A, Sanz-Rodriguez F, Blanco FJ. Hereditary hemorrhagic telangiectasia, a vascular dysplasia affecting the TGF-ß signaling pathway. Clinic Med Res 2006; 4: 66-78.
46. Blázquez-Medela M, García-Ortiz L, Gómez-Marcos MA, et al. Increased plasma soluble endoglin levels as an indicator of cardiovascular alterations in hypertensive and diabetic patients. BMC Med 2010; 8: 86-97.
47. Yanagisawa M, Masaki T. Molecular biology and biochemistry of the endothelins. Trends Pharmacol Sci 1989; 10: 374-378.
48. Levin ER. Endothelins. N Engl J Med 1995; 333: 356-363.
49. Letizia C, Iannaccone A, Cerci S, et al. Circulating endothelin-1 in non-insulin-dependent diabetic patients with retinopathy. Horm Metab Res 1997; 29: 247-251.
50. Morise T, Takeuchi Y, Kawano M, Koni I, Takeda R. Increased plasma levels of immunoreactive endothelin and von Willebrand factor in NIDDM patients. Diabetes Care 1995; 18: 87-89.
51. Bertello P, Veglio F, Pinna G, et al. Plasma endothelin in NIDDM patients with and without complications. Diabetes Care 1994; 17: 574-577.
52. Güvener N, Aytemir K, Aksöyek S, Gedik O. Plasma endothelin-1 levels in non-insulin dependent diabetes mellitus patients with macrovascular disease. Coron Artery Dis 1997; 8: 253-258.
53. El Boghdady NA, Badr GA. Evaluation of oxidative stress markers and vascular risk factors in patients with diabetic peripheral neuropathy. Cell Biochem Funct 2012; 30: 328-334.
54. Ak G, Buyukberber S, Sevinc A, et al. The relation between plasma endothelin-1 levels and metabolic control, risk factors, treatment modalities, and diabetic microangiopathy in patients with type 2 diabetes mellitus. J Diabetes Complications 2001; 15: 150-157.
55. Ozkul A, Ayhan M, Yenisey C, Akyol A, Guney E, Ergin FA. The role of oxidative stress and endothelial injury in diabetic neuropathy and neuropathic pain. Neuro Endocrinol Lett 2010; 31: 261-264.
56. Oku H, Kida T, Sugiyama T, Hamada J, Sato B, Ikeda T. Possible involvement of endothelin-1 and nitric oxide in the pathogenesis of proliferative diabetic retinopathy. Retina 2001; 21: 647-651.
57. Roldán-Pallarés M, Rollín R, Martínez-Montero JC, Fernández-Cruz A, Bravo-Llata C, Fernández-Durango R. Immunoreactive endothelin-1 in the vitreous humor and epiretinal membranes of patients with proliferative diabetic retinopathy. Retina 2007; 27: 222-235.
58. Pomero F, Allione A, Beltramo E, et al. Effects of protein kinase C inhibition and activation on proliferation and apoptosis of bovine retinal pericytes. Diabetologia 2003; 46: 416-419.
59. Chakravarthy U, Hayes RG, Stitt AW, McAuley E, Archer DB. Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products. Diabetes 1998; 47: 945-52.
60. Zhu H, Shi CH. Analysis of the diagnostic value of plasma endothelin for diabetic retinopathy using the receiver operating characteristic curve. Ophthalmic Res 2007; 39: 289-293.
61. Deng D, Evans T, Mukherjee K, Downey D, Chakrabarti S. Diabetes-induced vascular dysfunction in the retina: role of endothelins. Diabetologia 1999; 42: 1228-1234.
62. Kiryu-Seo S, Ohno N, Kidd GJ, Komuro H, Trapp BD. Demyelination increases axonal stationary mitochondrial size and the speed of axonal mitochondrial transport. J Neurosci 2010; 30: 6658-6666.
63. Keswani SC, Bosch-Marcé M, Reeda N, Fischer A, Semenza GL, Höke A. Nitric oxide prevents axonal degeneration by inducing HIF-1-dependent expression of erythropoietin. Proc Natl Acad Sci USA 2011; 108: 4986-4990.
64. Hounsom L, Corder R, Patel J, Tomlinson DR. Oxidative stress participates in the breakdown of neuronal phenotype in experimental diabetic neuropathy. Diabetologia 2001; 44: 424-428.
65. Cameron NE, Cotter MA. Pro-inflammatory mechanism in diabetic neuropathy: focus on the nuclear factor kappa B pathway. Curr Drug Targets 2008; 9: 60-67.